Goldman reiterates bullish rating on Amgen, sees Kyprolis sales ahead of consensus

|About: Amgen Inc. (AMGN)|By:, SA News Editor

Goldman is out with an update on IMS data for some of Amgen's (AMGN) key drugs.

"Sales are tracking slightly ahead of our estimates," analyst Terence Flynn says, adding that "Kyprolis, Epogen and Prolia are particularly strong, while Enbrel and Neulasta are tracking in-line and Aranesp is slightly below."

Flynn sees Q4 Kyprolis sales coming in at $76M versus consensus of $71M.

AMGN reiterated at Buy.

Price target is $130.